Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research note issued to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Up 13.9 %

NASDAQ:AKTX traded up $0.44 during midday trading on Tuesday, hitting $3.61. The company had a trading volume of 6,477 shares, compared to its average volume of 18,681. Akari Therapeutics has a 52-week low of $1.08 and a 52-week high of $5.20. The stock’s fifty day moving average price is $3.25 and its 200-day moving average price is $2.36.

Institutional Trading of Akari Therapeutics

An institutional investor recently raised its position in Akari Therapeutics stock. Omnia Family Wealth LLC boosted its holdings in Akari Therapeutics, Plc (NASDAQ:AKTX) by 48.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 87,628 shares of the biopharmaceutical company’s stock after purchasing an additional 28,511 shares during the period. Omnia Family Wealth LLC owned approximately 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent reporting period. Institutional investors own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.